Literature DB >> 28040278

Biventricular endomyocardial biopsy in patients with suspected myocarditis: Feasibility, complication rate and additional diagnostic value.

Thomas Stiermaier1, Felix Föhrenbach2, Karin Klingel3, Reinhard Kandolf3, Enno Boudriot2, Marcus Sandri2, Axel Linke2, Karl-Philipp Rommel2, Steffen Desch1, Gerhard Schuler2, Holger Thiele1, Philipp Lurz4.   

Abstract

BACKGROUND: Previous retrospective analyses have suggested that biventricular (BV) endomyocardial biopsy (EMB) is superior compared to selective left ventricular (LV) or right ventricular (RV) EMB. This study prospectively assessed the feasibility, safety and diagnostic performance of implementing a routine BV-EMB approach in patients with suspected myocarditis.
METHODS: Consecutive patients with clinically suspected myocarditis underwent EMB (n=136). Myocarditis was defined as ≥14 infiltrating leukocytes/mm2 in addition to enhanced human leukocyte antigen class II expression in professional antigen-presenting immune cells. The presence of viral genomes was assessed by nested (reverse transcriptase-) polymerase chain reaction.
RESULTS: BV-EMB was attempted in 132 patients (LV thrombus, n=3; complication during RV-EMB, n=1) and resulted in sufficient samples from both ventricles in 127 patients (96.2%). One major complication (pericardial tamponade requiring surgical revision) was observed during the 136 RV-EMB (0.7%). No severe complications occurred during the 132 LV procedures. Of the 127 patients with BV-EMB, myocarditis was diagnosed in 89 patients (70.1%). While 67 patients (75.3%) fulfilled the diagnostic criteria in both ventricles, the diagnosis of myocarditis was based on the results of LV-EMB only in 16 patients (18%) and of RV-EMB only in 6 patients (6.7%). Viral genomes were found in 45 of the 127 patients (35.4%) with evidence of virus genome only in the left ventricle in 10 patients (22.2%) and only in the right ventricle in 3 patients (6.7%).
CONCLUSIONS: Implementing a routine BV-EMB approach is feasible and safe. In patients with suspected myocarditis, BV-EMB yields superior diagnostic performance compared to selective RV- or LV-EMB.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Complications; Diagnosis; Endomyocardial biopsy; Myocarditis

Mesh:

Year:  2016        PMID: 28040278     DOI: 10.1016/j.ijcard.2016.12.103

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

1.  CMR-guidance of passively tracked endomyocardial biopsy in an in vivo porcine model.

Authors:  P Behm; M Gastl; A Jahn; A Rohde; S Haberkorn; S Krueger; S Weiss; B Schnackenburg; M Sager; K Düring; H Clogenson; P Horn; R Westenfeld; M Kelm; M Neizel-Wittke; F Bönner
Journal:  Int J Cardiovasc Imaging       Date:  2018-06-19       Impact factor: 2.357

2.  [MINOCA-myocardial infarction with non-obstructive coronary arteries].

Authors:  C Hamm; C W Hamm
Journal:  Herz       Date:  2018-12       Impact factor: 1.443

3.  Silent myocarditis in systemic sclerosis detected by cardiovascular magnetic resonance using Lake Louise criteria.

Authors:  Sophie Mavrogeni; Loukia Koutsogeorgopoulou; Georgia Karabela; Efthymios Stavropoulos; Gikas Katsifis; John Raftakis; Sotiris Plastiras; Michel Noutsias; George Markousis-Mavrogenis; Genovefa Kolovou
Journal:  BMC Cardiovasc Disord       Date:  2017-07-17       Impact factor: 2.298

Review 4.  T2 mapping and T2* imaging in heart failure.

Authors:  A S Lota; P D Gatehouse; R H Mohiaddin
Journal:  Heart Fail Rev       Date:  2017-07       Impact factor: 4.214

5.  Right ventricular dominant myocarditis requiring cardiac resynchronization therapy-defibrillator: a case report.

Authors:  Takanori Sato; Togo Iwahana; Ryo Ito; Yusuke Kondo; Yoshio Kobayashi
Journal:  ESC Heart Fail       Date:  2021-10-16

6.  Practical aspects of endomyocardial left ventricular biopsy - own experience.

Authors:  Krzysztof Dyrbuś; Przemysław Trzeciak; Jacek Piegza; Adam Krajewski; Grzegorz Słonka; Alicja Nowowiejska-Wiewióra; Mariusz Gąsior
Journal:  Postepy Kardiol Interwencyjnej       Date:  2021-12-30       Impact factor: 1.426

7.  Parvovirus B19 Myocarditis of Fulminant Evolution.

Authors:  Michael Spartalis; Eleni Tzatzaki; Eleftherios Spartalis; Christos Damaskos; Sophie Mavrogeni; Vassilis Voudris
Journal:  Cardiol Res       Date:  2017-08-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.